MedTrace Logo

Peri-neural Dexmedetomidine Versus Dexamethasone for Supraaclavicular Block Adjuvant to Bupivacaine Supraclavicular Brachial Plexus Block

NCT04694105 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2021-01-05

No results posted yet for this study

Summary

to assessthe impact of addition of Dexmedetomidine or Dexamethasone to Bupivacaine, on Duration of analgesia (time in hours to the first report of postoperative pain )at the surgical site

Conditions

  • Brachial Plexus Block

Interventions

DRUG

Dexmedetomidine injection

perineural injection of Bupivacaine 30 ml 0.25% combined with 50 microgram (0.5 ml) peri-neural dexmedetomidine plus 1.5 ml normal saline

DRUG

Dexamethasone

perineural injection of Bupivacaine 30 ml 0.25% combined with 4 mg peri neural dexamethasone (2 ml)

DRUG

saline

perineural injection of Bupivacaine 30 ml 0.25% combined with 2 ml normal saline

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Tarek A Radwan, MD · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2019-12-01
Completion
2020-01-12

Countries

  • Egypt

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04694105 on ClinicalTrials.gov